NIR-Guided Sentinel Lymph Node Mapping in Melanoma

Melanoma Clinical Trial

Official title:

Real-Time NIR-Guided Sentinel Lymph Node Mapping in Melanoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01121718
• Other study ID #: 10-039
• Status: Completed
• Phase: Phase 1
• First received: May 6, 2010
• Last updated: February 2, 2017
• Start date: September 2010
• Est. completion date: April 2012

Study information

• Verified date: February 2017
• Source: Dana-Farber Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will try to define an appropriate dose of the investigational drug indocyanine green (ICG) in combination with near infrared (NIR) imaging to use for future studies.

ICG is a dye which has been in use since the 50s, and is approved for testing liver function and measuring blood flow from the heart. It has been used in studies to map lymphatic pathways in lung and breast cancer and information from those studies suggest it may help identify lymph nodes associated with melanoma. ICG can be detected within the body using near-infrared light cameras.

In this study the investigators are looking at how easily ICG can get to the first lymph node (sentinel lymph node [SLN]) associated with melanoma, whether the investigators can see the path of the ICG and the SLN using a near infrared camera, and what dose of ICG works the best. While the current method for SNL mapping, known as lymphoscintigraphy, is effective it does provide a small amount of radiation. This study will compare the investigators results to the standard procedure.

Description:

At the time of surgery, you will undergo a lymphoscintigraphic procedure which is standard of care for patients with melanoma. You will also receive a dose of ICG mixed with human serum albumin. This will be administered in four small injections immediately around your tumor or the tumor scar if it has already been removed. Pictures of the ICG solution will be taken with the NIR camera and the progression of the dye along the lymphatic channel from your tumor to the SLN will be monitored.

As each lymph node is removed, pictures will be taken to see if the ICG dye has entered and colored that node. We will compare this technique with the results from the lymphoscintigraphy to measure accuracy.

Patients will be followed for at least one hour post injection for adverse events. The patient will then be taken off of the study. The results from each intervention will subsequently analyzed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed melanoma and an appropriate surgical candidate for a sentinel lymph node biopsy

• Stage of disease conducive to sentinel lymph node biopsy as determined by oncologic surgeon

• Receiving a planned lymphoscintigraphy procedure

Exclusion Criteria:

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergy

• Pregnant or breast-feeding

Related Conditions & MeSH terms

• Melanoma

Intervention

Drug:
• ICG Intervention
NIR-guided sentinel lymph node mapping with indocyanine green (ICG)

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Brigham and Women's Hospital	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	Beth Israel Deaconess Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility	To determine the feasibility of real-time intraoperative NIR lymphatic mapping with concurrent identification of the sentinel lymph node in human melanoma using indocyanine green.	We will analyze data immediately following each case, and analyze all collected data at 6 month intervals
Secondary	Comparison of SLN identification rate between near-infrared mapping and lymphoscintigraphy.		We will analyze data immediately following each case, and analyze all collected data at 6 month intervals